Anti-IL–20 monoclonal antibody (mAb) 7E decreased osteolytic bone lesions in mouse models of breast cancer and protected ovariectomized mice against osteoporotic bone loss, both of which support the notion that IL–20 is critical for regulating of tumor-mediated osteolysis. Here, IL20 is linked to breast cancer.